UPDATE: Oppenheimer Initiates Coverage on Karyopharm Therapeutics on Novel Mechanism with Broad Applicability in Oncology

In a report published Monday, Oppenheimer analyst David Ferreiro initiated coverage on Karyopharm Therapeutics (NASDAQ: KPTI ) with an Outperform rating and $23.00 price target. In the report, Oppenheimer noted, “Karyopharm Therapeutics (KPTI) is focused on the development of novel small-molecule therapeutics targeting the nuclear export protein XPO1. KPTI's lead